



Kawamori et al. Cardiovascular Diabetology 2013, 12:131
http://www.cardiab.com/content/12/1/131ORIGINAL INVESTIGATION Open AccessBaseline and 1-year interim follow-up assessment
of Japanese patients initiating insulin therapy
who were enrolled in the cardiovascular risk
evaluation in people with type 2 diabetes on
insulin therapy study: an international,
multicenter, observational study
Ryuzo Kawamori1*†, Koichi Node2†, Toshiaki Hanafusa3†, Yoshihito Atsumi4†, Yusuke Naito5† and Yoshitomo Oka6†Abstract
Background: The Cardiovascular Risk Evaluation in people with type 2 Diabetes on Insulin Therapy (CREDIT) study
is an international, multicenter, observational study designed to assess metabolic parameters and cardiovascular risk
of patients with type 2 diabetes mellitus (T2DM) on insulin therapy. The present report summarizes results at
baseline and 1-year follow-up for the cohort of Japanese patients.
Methods: Male and female patients (n = 511), aged >40 years, with T2DM for >1 year, treated with insulin therapy
for ≥1 month and <6 months were eligible for participation in the study. Glycemic and lipid parameters, duration
of diabetes, diabetic complications, oral antidiabetic medications, and all hypoglycemic episodes were recorded.
Effectiveness was assessed based on changes in clinical parameters and attainment of target HbA1c levels. Safety
was evaluated based on episodes of hypoglycemia and weight gain.
Results: At baseline, the mean ± SD duration of diabetes was 11.8 ± 8.8 years. Microvascular and macrovascular
diabetic complications were present in 83.4% and 25.1% of patients, respectively. At the 1-year follow-up, significant
improvements were observed in mean HbA1c (10.3 ± 2.0% vs. 7.5 ± 1.3%, P < .001), fasting plasma glucose (217.3 ±
80.8 mg/dL vs. 139.0 ± 48.7 mg/dL, P < .001), and postprandial plasma glucose levels (296.1 ± 96.0 mg/dL vs. 178.2 ±
68.6 mg/dL, P < .001) compared with baseline. Mean total cholesterol (P < .001), low-density lipoprotein cholesterol
(P < .001), triglycerides (P < .01), and diastolic blood pressure (P < .01) also significantly decreased. Good glycemic
control (HbA1c < 7.0%) was achieved in 40% of patients at the 1-year follow-up. Glycemic control tended to be
better in patients with lower baseline HbA1c levels (P < .01). Patients with a shorter duration of diabetes were more
likely to achieve glycemic control and discontinue insulin for diabetes control at the 1-year follow-up (P < .05 for
trend). Symptomatic hypoglycemic episodes occurred in 21.8% of patients over 6 to 12 months.
Conclusions: Our results suggest that insulin treatment is an effective and safe therapeutic option in Japanese
patients with T2DM, and earlier insulin initiation might be associated with better glycemic control.
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The incidence of type 2 diabetes mellitus (T2DM) is dra-
matically increasing worldwide due to increasing obesity,
a more sedentary lifestyle, and aging of the population.
In 2012, diabetes was estimated to be present in 371 mil-
lion people worldwide; it is predicted that the prevalence
will increase to 552 million by 2030 [1]. Likewise in
2012, the estimated prevalence of diabetes in Japan was
7.1 million people, and this value is expected to increase
to 10.2 million by 2030 [1]. Diabetes and its associated
complications have become a major cause of morbidity
and mortality, representing one of the greatest healthcare
challenges facing the world today [2].
Many epidemiologic studies and national registries on
diabetes have been conducted at national or regional
levels, particularly in developed countries. These studies
provide useful information for assessing the current qual-
ity of care in diabetic patients and for evaluating compli-
ance with national treatment guidelines [3-9]. However,
few studies have focused on diabetes treatment with insu-
lin, one of the most reliable agents for glycemic control. In
particular, few data are available regarding the roles of
baseline HbA1c levels and the duration of diabetes for
predicting future need for insulin therapy. Furthermore,
early intervention with insulin in T2DM may prevent dis-
ease progression as well as preserve insulin secretion from
pancreatic beta cells [10].
The Cardiovascular Risk Evaluation in patients with
type 2 Diabetes on Insulin Therapy (CREDIT) study is an
international, multicenter (314 centers), non-interventional
investigation of the effects of long-term (4 years) glycemic
control following initiation of insulin treatment on the risk
reduction of cardiovascular (CV) events associated with
T2DM in a large cohort of patients (n = 3,031) [11]. This
report provides details from the 1-year interim analysis of
Japanese patients involved in the CREDIT study, includ-
ing baseline characteristics at insulin initiation and




The CREDIT is a global, multicenter, observational,
non-interventional study in medical practice designed to
investigate the effects of long-term glycemic control with
insulin treatment on the risk reduction of CV events as-
sociated with T2DM [11]. The total follow-up period
was 4 years, with assessments every 6 months from
baseline. The present report details the results for the
Japanese cohort of patients at baseline and at the 1-year
follow-up.
Participating investigators included randomly selected
physicians specializing in diabetes and primary care
physicians who are experts in insulin therapy. Eachinvestigator was given a 2-month instruction period with
respect to the study protocol, enrolling approximately 10
(range, 5–30) consecutive eligible patients over a 12-
month recruitment period. Japanese participants were
recruited from January to December 2007. The study
was approved by local ethics committees according to
the regulations.
Study population
Male or female patients, aged >40 years, with T2DM
for >1 year and who were initiating insulin therapy were
eligible. Other inclusion criteria included duration of
insulin therapy ≥1 month and <6 months before registra-
tion, regardless of the mode of administration, as well as
HbA1c levels assessed within 3 months prior to initiation
of insulin therapy and an expectation of long-term insulin
therapy. Exclusion criteria included type 1 diabetes, non-
insulin-treated T2DM, diabetes secondary to pancreatic
damage, corticosteroid treatment, endocrine impairment,
expectation of short-term insulin therapy (e.g., gestational
diabetes, pancreatic cancer, or surgery), participation in
another clinical study using insulin, or pregnancy at
recruitment.
All patients provided written, informed consent to
participate in this study, which was conducted in accord-
ance with the principles of the Declaration of Helsinki
and subsequent amendments, and the guidelines for
Good Epidemiology Practice.
Data analysis
The following patient data were recorded at registration:
background (gender, age, and disease duration); history
of diabetic complications (retinopathy, peripheral neur-
opathy, nephropathy including microalbuminuria [30–
299 mg/24 h], macroalbuminuria [≥300 mg/24 h], and
renal failure [confirmed by creatinine clearance], and
dialysis and/or transplantation); history of macrovascular
disease (i.e., myocardial infarction, stable angina, severe
unstable angina leading to hospitalization, heart failure,
stroke, transient ischemic attack, peripheral vascular
disease, myocardial revascularization, peripheral revas-
cularization, or lower limb amputation); use of oral
antidiabetic (OAD) medication at initiation of insulin
therapy; and details of insulin therapy at initiation (date,
reason, insulin type [e.g., basal, short-acting, premix,
others], mode of administration, dosage, and frequency
of administration). Any change in insulin therapy dur-
ing the study was recorded along with the reason for
the change.
The following data were recorded at every 6-month
visit: systolic blood pressure (SBP), diastolic blood pres-
sure (DBP), body weight, body mass index (BMI), HbA1c
levels (HbA1c was collected as the Japan Diabetes Society
value and was normalized to 6.0%, regarding the normal
Table 1 Baseline patient characteristics
Parameter1) No. of patients (categorized data)
or mean ± SD (qualitative data)
Age at insulin initiation, years
[N = 511]
62.2 ± 10.0
Gender [N = 511]
Male 326 (63.8%)
Female 185 (36.2%)
Duration of diabetes, years
[N = 504]
11.8 ± 8.8
Duration of diabetes category
[N = 504]
<5 years 99 (19.6%)
≥5, <10 years 125 (24.8%)
≥10, <15 years 134 (26.6%)
≥15 years 146 (29.0%)
HbA1c (%) [N = 506] 10.3 ± 2.0
HbA1c category [N = 506]
≤8.0% 57 (11.3%)
>8.0%, ≤10.0% 197 (38.9%)
>10.0%, ≤12.0% 169 (33.4%)
>12.0% 83 (16.4%)
FPG (mg/dL) [N = 254] 217.3 ± 80.8
PPG (mg/dL) [N = 329] 296.1 ± 96.0
BMI (kg/m2) [N = 490] 23.9 ± 4.0
Insulin regimen
Basal 32 (6.3%)







Nephropathy [N = 500] 304 (60.8%)
Microalbuminuria [N = 498] 178 (35.7%)
Macroalbuminuria [N = 505] 185 (36.6%)
Renal failure [N = 509] 78 (15.3%)
Retinopathy [N = 508] 209 (41.1%)
Peripheral neuropathy [N = 509] 265 (52.1%)
Foot ulcer [N = 510] 7 (1.4%)
Macrovascular disease [N = 510] 128 (25.1%)
Abbreviations: BMI body mass index, FPG fasting plasma glucose, PPG
postprandial plasma glucose.
1)Data are missing for some patients; numbers with available data are shown
in parentheses.
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6.0/normal upper limit; this method was the standard pro-
cedure used in the CREDIT study), fasting plasma glucose
(FPG) levels, postprandial plasma glucose (PPG) levels,
incidence of symptomatic and severe hypoglycemia,
levels of plasma lipids (total cholesterol, high-density
lipoprotein (HDL) cholesterol, low-density lipoprotein
(LDL) cholesterol, and triglycerides), and serum creatin-
ine levels. Symptomatic hypoglycemia was defined by
typical symptoms and plasma glucose levels <70 mg/dL.
Severe hypoglycemia was defined as an event with clin-
ical symptoms that were considered to result from
hypoglycemia in which the patient required the assist-
ance of another person and had one of the following:
plasma glucose level <36 mg/dL or requirement for oral
carbohydrate, intravenous glucose, or glucagon admin-
istration for resolution. Hypoglycemia was further de-
fined as nocturnal if it occurred during night-time sleep.
Effectiveness was assessed based on changes in the
glycemic control index, rate of attaining HbA1c level
<7.0%, and rate of withdrawal from insulin therapy.
Safety was evaluated based on the rate of hypoglycemia
during the 6 months before the 1-year follow-up visit
and weight gain.
Statistical analysis
For baseline characteristics, mean values were expressed
with 1 standard deviation (SD) or proportions were
shown for categorical variables. The paired t-test was
used to compare continuous variables at baseline and at
1-year follow-up. Number of patients achieving HbA1c
level <7.0%, number of withdrawals at 1-year follow-up,
and number of hypoglycemic episodes were tested using
the Cochran-Armitage test or trend test using analysis of
variance according to baseline HbA1c levels and dur-
ation of diabetes. Student’s t-test and χ2 test (or Fisher’s
exact test, if the cell numbers were less) with Hochberg
multiple comparison adjustments [12] were used for pair-
wise comparisons between categories. The level of signifi-
cance was set at P < .05. Data analysis was primarily
performed using SAS software version 8.2 (SAS Institute
Inc., Cary, NC), with some analysis conducted using R
2.13.1 [13] for Hochberg multiple comparison adjustment.
Results
A total of 511 patients were recruited by 63 investigators
(94.3% of whom were diabetes specialists) at different in-
stitutes throughout Japan (63.6% in hospitals and 29.2%
at clinics). Insulin administration was started due to
poor glycemic control in 87.7% of patients.
Baseline patient characteristics are shown in Table 1.
Mean age was 62.2 ± 10.0 years, and approximately two-
thirds of patients were men. The mean duration of dia-
betes was 11.8 ± 8.8 years, and 55.6% had diabetes for≥10 years. Mean baseline HbA1c level was 10.3 ± 2.0%.
Administration of premix insulin was the most fre-
quently used treatment (36.8%). Microvascular diabetic
complications were present in 83.4% of patients, and
Table 2 Anthropometric, vital, and laboratory data at baseline and 1-year follow-up
Parameter Baseline 1-year follow-up Change P-value1)
n mean ± SD n mean ± SD n mean ± SD
Body weight, kg 491 62.2 ± 12.4 434 63.5 ± 11.8 434 1.3 ± 4.3 ***
BMI, kg/m2 490 23.9 ± 4.0 433 24.4 ± 3.7 433 0.5 ± 1.6 ***
HbA1c, % 506 10.3 ± 2.0 482 7.5 ± 1.3 478 −2.7 ± 2.2 ***
FPG, mg/dL 254 217.3 ± 80.8 137 139.0 ± 48.7 91 −79.0 ± 92.9 ***
PPG, mg/dL 329 296.1 ± 96.0 380 178.2 ± 68.6 256 −115.9 ± 111.1 ***
Total cholesterol, mg/dL 439 201.4 ± 43.6 309 187.7 ± 35.9 286 −12.6 ± 44.2 ***
LDL-cholesterol, mg/dL 294 122.0 ± 34.0 383 110.5 ± 28.3 239 −11.0 ± 32.0 ***
HDL-cholesterol, mg/dL
Men 277 50.0 ± 13.7 268 53.2 ± 15.2 234 3.1 ± 11.3 ***
Women 163 56.8 ± 15.9 151 58.1 ± 15.7 135 2.3 ± 12.1 *
Triglycerides, mg/dL 465 159.7 ± 132.0 447 138.0 ± 85.3 410 −19.7 ± 128.3 **
Creatinine, mg/dL 404 0.76 ± 0.42 422 0.86 ± 0.58 334 0.11 ± 0.66 **
SBP, mmHg 474 132.1 ± 18.5 466 132.8 ± 17.7 435 1.0 ± 20.6 N.S.
DBP, mmHg 474 76.5 ± 11.7 466 74.5 ± 10.8 435 −1.9 ± 12.4 **
Abbreviations: BMI body mass index, DBP diastolic blood pressure, FPG fasting plasma glucose, Hb hemoglobin, HDL high-density lipoprotein, LDL low-density
lipoprotein, PPG postprandial plasma glucose, SBP systolic blood pressure.
1)Paired t-test.
N.S. not statistically significant, *P < .05, **P < .01, ***P < .001.
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25.1% of patients.
Changes in anthropometric, vital, and laboratory data
at 1-year follow-up compared with baseline are shown in
Table 2. At the 1-year follow-up, significant increases
were observed in mean body weight (1.3 ± 4.3 kg, P < .001)
and BMI (0.5 ± 1.6 kg/m2, P < .001), and significant de-
creases were observed in levels of mean HbA1c (−2.7 ±
2.2%, P < .001), FPG (−79.0 ± 92.9 mg/dL, P < .001), and
PPG (−115.9 ± 111.1 mg/dL, P < .001). All plasma lipid pa-
rameters significantly improved. Mean serum creatinine
levels increased significantly (0.11 ± 0.66 mg/dL, P < .01).
Mean DBP was significantly decreased, whereas no signifi-
cant changes were seen in mean SBP.
The insulin regimen was found to have changed at the
1-year follow-up compared with baseline (Table 3). The
use of basal + short-acting insulin and a short-acting in-
sulin alone regimen decreased by approximately 10%,Table 3 Insulin regimen at initiation and at 1-year follow-up
Insulin regimen At insulin initiation (N = 511)
N (%) Mean dose ± SD (Unit)
Basal 32 (6.3%) 7.2 ± 2.9
Basal + short-acting 134 (26.2%) Basal: 5.0 ± 2.5 Short: 14
Short-acting 130 (25.4%) 12.8 ± 8.0
Premix 188 (36.8%) 12.3 ± 7.3
Others 27 (5.3%) -
No insulin 0 -whereas use of a premixed regimen increased by 10%.
Approximately 5% of patients were converted to other
regimens, whereas the remaining 5% were withdrawn
from insulin therapy mainly due to improvement in dia-
betes control. Altogether 20 withdrawals (74%) were
due to improved glycemic control and/or HbA1c <7.0%
at 1-year follow-up, while 4 were due to other reasons
(1 for hypoglycemia, 1 for prevention of hypoglycemia,
1 for presence of anti-insulin antibodies, and 1 for
inability to self-inject insulin), and 3 were due to un-
specified reasons.
Data regarding use of OADs before insulin initiation,
at insulin initiation, and at the 1-year follow-up are
summarized in Table 4. Approximately 19% of patients
began insulin directly after trying diet and exercise ther-
apy without using OADs. The remaining patients used
OADs before insulin initiation, and most used ≥2 OADs
concurrently. Sulfonylureas were the most frequently1-year follow-up (N = 488)
N (%) Mean dose ± SD (Unit)
35 (7.2%) 11.0 ± 4.5
.9 ± 6.9 84 (17.2%) Basal: 10.2 ± 8.4 Short: 19.4 ± 8.0
54 (11.1%) 17.6 ± 10.3
230 (47.1%) 20.4 ± 11.5
58 (11.9%) -
27 (5.5%) -
Table 4 Oral antidiabetic drug use before insulin











No. of oral antidiabetic
drugs, n (%)
0 98 (19.2%) 262 (51.3%) 229 (46.9%)
1 119 (23.3%) 110 (21.5%) 127 (26.0%)
2 170 (33.3%) 91 (17.8%) 94 (19.3%)
≥3 124 (24.3%) 48 (9.4%) 38 (7.8%)
Drug class, n (%)
Biguanides 148 (29.0%) 109 (21.3%) 120 (24.6%)
Sulfonylureas 357 (69.9%) 133 (26.0%) 99 (20.3%)
Glinides 28 (5.5%) 10 (2.0%) 78 (16.0%)
Thiazolidinediones 134 (26.2%) 80 (15.7%) 36 (7.4%)
α-glucosidase
inhibitor
177 (34.6%) 107 (20.9%) 104 (21.3%)
Others 5 (1.0%) 5 (1.0%) 0
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50% of patients stopped OAD medication at the initiation
of insulin therapy; results were similar at the 1-year
follow-up. There was little change in the percentages of
use of each OAD except for thiazolidinediones between
the baseline and 1-year follow-up results; the use of
thiazolidinediones decreased after 1 year.
Good glycemic control was attained in 40% (193/482)
of patients at the 1-year follow-up; the glycemic control
rate at the 1-year follow-up was significantly higher in pa-
tients with a lower baseline HbA1c values (≤8.0%) than in
patients with higher baseline HbA1c values (P < .01 for
Cochran-Armitage test and P < .05 for pairwise comparison
of ≤8.0% with >8.0%, ≤10.0% or >10.0%, ≤12.0%, Table 5
and Figure 1). Furthermore, 5.5% of patients (27/488)
discontinued insulin injections by the time of the 1-year
follow-up visit; their mean HbA1c levels had decreased
from 10.5 ± 2.1% to 6.8± 1.3% (data not shown). The
change in HbA1c from baseline in patients with a shorter
duration of diabetes was significantly greater than thoseTable 5 Achieved HbA1c Level <7.0%, withdrawal at 1 year, a
All1) ≤8.
Achievement of HbA1c level <7.0% 193/482 (40.0%) 33/5
Withdrawal from insulin at 1 year 27/488 (5.5%) 5/55
Patients with any hypoglycemic episodes 105/482 (21.8%) 15/5
Number of hypoglycemic episode/patient 1.44 ± 5.18 1.85
Patients with severe hypoglycemic episodes 8/483 (1.7%) 3/54
Number of severe hypoglycemic episodes/patients 0.03 ± 0.35 0.17
1)Including patients with missing baseline HbA1c level data.
2)Trend test by Cochran-Armitage test for categorical variables and analysis of varia
3)Category score = (2,1,1,1).
N.S. not statistically significant, *P < .05, **P < .01.with a longer duration (<5 years: -3.5 ± 2.4%; ≥5 years,
<10 years: -2.7 ± 2.1%; ≥10 years, <15 years: -2.7 ± 2.3%;
and ≥15 years: -2.4 ± 1.9%; P < .01 for <5 years vs. ≥15 years
using t test with Hochberg’s multiple comparison adjust-
ment). There was a statistically significant inverse linear
trend in the rate of withdrawal from insulin according to
duration of diabetes (P < .05), but no statistically significant
difference was seen between any categorical pairs (Table 6).
Symptomatic hypoglycemic episodes occurred in 105
of 482 (21.8%) patients during 6 to 12 months, and mean
frequency of symptomatic hypoglycemia was 1.44 ± 5.18
episodes per patient (nocturnal: 0.04 ± 0.47 episodes per
patient). Severe hypoglycemic episodes occurred in 8 of
483 (1.7%) of patients, and the mean frequency of severe
hypoglycemia was 0.03 ± 0.35 episodes per patient. There
were no cases of severe nocturnal hypoglycemia. A
statistically significant inverse linear trend of severe
hypoglycemia was observed according to baseline HbA1c
levels (P < .05 for the number of patients and P < .01 for
the mean frequency of episodes), but no statistically sig-
nificant difference was seen between any categorical pairs
(Table 5).
Discussion
The CREDIT Japan interim analyses demonstrated the
baseline characteristics of Japanese patients with T2DM
who initiated insulin therapy. At baseline, the mean age
was 62.2 years, mean disease duration was 11.8 years, and
mean HbA1c level was 10.3%. Furthermore, 83.4% had
microvascular complications, and 25.1% had macrovascular
complications. In addition, the 1-year follow-up results
demonstrated that although mean body weight, BMI, and
serum creatinine levels increased significantly, 40% of pa-
tients treated with insulin achieved good glycemic control,
and 5.5% were withdrawn from insulin therapy due to im-
provement in HbA1c level. There was a higher probability
of achieving target HbA1c levels if HbA1c levels at initi-
ation of insulin therapy were lower. The tendency to
withdraw from insulin therapy due to improved glycemic
control was higher if the duration of diabetes at initiation
was shorter.nd hypoglycemic episodes by baseline levels
0% >8.1%, ≤10.0% >10.0%, ≤12.0% >12.0% P2)
5 (60.0%) 69/189 (36.5%) 60/161 (37.3%) 29/73 (39.7%) **3)
(9.1%) 7/191 (3.7%) 9/164 (5.5%) 6/74 (8.1%) N.S.
4 (27.8%) 39/189 (20.6%) 34/162 (21.0%) 16/73 (21.9%) N.S.
± 6.43 1.13 ± 3.62 1.56 ± 5.19 1.58 ± 7.23 N.S.
(5.6%) 3/190 (1.6%) 1/162 (0.6%) 1/73 (1.4%) *3)
± 0.97 0.02 ± 0.18 0.01 ± 0.08 0.01 ± 0.12 **
nce with contrast statement for numerical variables.
Figure 1 Percentage of patients achieving HbA1c level <7.0% at the 1-year follow-up compared with baseline. *P < .05, χ2 test with
Hochberg’s multiple comparison adjustment.
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mentioned relationship, although some studies have in-
vestigated baseline HbA1c levels in order to clarify
optimal insulin therapy of T2DM. The following data-
base studies only referred to a snap-shot of mean HbA1c
levels in patients who had started insulin therapy. The
Swedish National Diabetes Register (N = 61,890) showed
that the mean HbA1c level was 7.2–7.9% and that the
HbA1c levels were independent of disease duration [4].
The Scottish Care Information-Diabetes Collaboration
database registry (N = 36,254) [3] showed that mean
HbA1c levels were 8.6–9.4% in type 1 or 2 diabetes pa-
tients treated with insulin. The Hong Kong Diabetes
Registry (N = 7,549) [8] showed that mean HbA1c levels
were 7.9% (insulin alone) or 8.6% (insulin plus OADs).
Compared with previous data at insulin initiation, our
results show higher mean baseline HbA1c levels and
longer mean diabetes duration. CoDiC® Japanese data
showed that insulin therapy was started earlier (mean
HbA1c levels, 8–9%) than that in our patients [5,6], and
that study concluded that early-stage initiation of insulin
therapy was related to satisfactory glycemic control. A
large retrospective database study in the United States
demonstrated that patients who began intermediate-Table 6 Achieved HbA1c Level <7.0%, withdrawal at 1 year, a
All <5
Achievement of HbA1c level <7.0% 193/482 (40.0%) 44/9
Withdrawal from insulin at 1 year 27/488 (5.5%) 9/95
Patients with any hypoglycemic episodes 105/482 (21.8%) 19/9
Number of any hypoglycemic episodes/patient 1.44 ± 5.18 0.84
Patients with severe hypoglycemic episodes 8/483 (1.7%) 2/95
Number of severe hypoglycemic episodes/patient 0.03 ± 0.35 0.03
1)Trend test by Cochran-Armitage test for categorical variables and analysis of varia
N.S. not statistically significant, *P < .05.acting insulin with neutral protamine Hagedorn (NPH)
insulin or long-acting insulin with insulin glargine had
mean HbA1c values of 8.91% and 9.28%, respectively [7].
In addition to differences in study designs, there are
several reasons for this difference. The lack or lower
accessibility of long-acting insulin analogues (insulin
glargine and detemir) during the enrollment period in
Japan may be one of the reasons. These analogues allow a
wide range of therapeutic options, from convenient add-
on therapy to OADs (basal-supported oral therapy; BOT)
to basal-bolus therapy (i.e., basal + short-acting regimen).
Currently, BOT is recognized as a convenient and patient-
friendly option for insulin initiation. The other reason
may be the dominance of in-hospital initiation (63.6%) of
insulin therapy; many patients avoid inpatient initiation
for various reasons, such as less flexibility to the patient’s
lifestyle, leading to delayed initiation. These observations
suggest that our cohort potentially represents a more
difficult-to-treat and resistant patient population. Further
studies are warranted to clarify these details.
Differences in treatment guidelines may also affect the
timing of insulin initiation. The consensus statement of the
American Diabetes Association (ADA) and the European
Association for the Study of Diabetes (EASD) clearly statesnd hypoglycemic episodes by duration of diabetes
years ≥5, <10 years ≥10, <15 years ≥15 years P1)
5 (46.3%) 49/120 (40.8%) 50/129 (38.8%) 47/132 (35.6%) N.S.
(9.5%) 8/121 (6.6%) 7/129 (5.4%) 3/137 (2.2%) *
5 (20.0%) 17/120 (14.2%) 39/127 (30.7%) 29/134 (21.6%) N.S.
± 2.72 1.06 ± 4.81 2.61 ± 7.87 1.11 ± 3.22 N.S.
(2.1%) 1/120 (0.8%) 2/128 (1.6%) 3/134 (2.2%) N.S.
± 0.23 0.01 ± 0.09 0.02 ± 0.12 0.07 ± 0.62 N.S.
nce with contrast statement for numerical variables.
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recommends timely intensification by changing regimens
in patients uncontrolled on their current therapy over
3 months [14], though this statement was recently updated
in 2012 and addressed individualized rather than uniform
treatment [15]. In contrast, Japanese diabetes therapeutic
guidelines do not clearly specify the timing or methods for
insulin initiation and intensification, although the guide-
lines recommend achieving goal glycemic values [16].
The results of this study revealed that lower HbA1c
levels and a shorter duration of diabetes at insulin initi-
ation were associated with better glycemic control and
withdrawal due to HbA1c improvement; hence, earlier
intervention is important for successful glycemic control
in patients with T2DM. Earlier use of insulin leads to a
decreased subsequent disease risk and the preservation
of beta cell function. Several clinical trials or systematic
review of clinical trials support the results of the present
study. The Outcome Reduction with an Initial Glargine
Intervention (ORIGIN) trial [17] showed no increase in
clinical CV events with insulin glargine for early T2DM
after 6.2 years, and a substudy of the ORIGIN, the Glu-
cose Reduction and Atherosclerosis Continuing Evalu-
ation Study (ORIGIN-GRACE) [18] also revealed that
long-term treatment with insulin might result in CV
event reduction. Hemmingsen et al. [19] summarized that
there was no evidence or even towards improved CV mor-
tality with metformin and insulin, compared with insulin
alone in T2DM. Furthermore, Holman et al. [20] revealed
that intensive intervention immediately after the diagnosis
of diabetes leads to decreased CV risk after a long period
in the United Kingdom Prospective Diabetes Study
(UKPDS). Data from intensive insulin treatment with con-
tinuous subcutaneous insulin infusion [10,21] demon-
strated several pieces of evidence associated with beta cell
preservation and restoration compared with conventional
OAD treatment.
In addition to information regarding glycemic control,
patients in the present study showed improvement in
CV risk factors (lipid profile [22-24] and DBP [25,26])
during the 1-year follow-up. The complete CREDIT 4-
year follow-up data will reveal the long-term effects of
insulin therapy on CV event reduction.
Several limitations regarding our results must be
addressed. First, the CREDIT study was an observational
study with no intervention or control group. To increase
data reliability compared with previous retrospective or
cross-sectional studies, our study was designed as a pro-
spective cohort study. Furthermore, participating investi-
gators were randomly selected to minimize potential
bias. In addition, participating investigators were dia-
betes specialists (94.3%), which likely enhanced data
reliability and accuracy. Second, although the grouping
of insulins into categories enabled us to include anadequate number of subjects in each insulin group, this
method allowed both human and analogue insulins to
be included in the same category. Third, the data do not
include information on patients treated with long-acting
insulin analogues.
Conclusions
Improvements in both glycemic control as well as lipid
parameters at 1-year after insulin initiation in this sub-
group analysis of the CREDIT study suggest that insulin
treatment is an effective and safe therapeutic option in
Japanese patients with T2DM. Additionally, more appro-
priate timing regarding insulin initiation (i.e., earlier than
that used in 2007) may be important for achieving better
glycemic control.
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